No Beneficial Effects Seen for Cyclosporine A in Reperfused MI

Share this content:
No Beneficial Effects Seen for Cyclosporine A in Reperfused MI
No Beneficial Effects Seen for Cyclosporine A in Reperfused MI

WEDNESDAY, Jan. 27, 2016 (HealthDay News) -- A single intravenous cyclosporine A (CsA) bolus just before primary percutaneous coronary intervention has no beneficial effects on ST-segment resolution in reperfused myocardial infarction (MI), according to a study published in the Feb. 2 issue of the Journal of the American College of Cardiology.

Filippo Ottani, M.D., from the Ospedale GB Morgagni in Forli, Italy, and colleagues examined the effect of CsA on ST-segment resolution. Patients (age 63 ± 12 years) from 31 cardiac care units, with large ST-segment elevation MI and Thrombolysis In Myocardial Infarction flow grade 0 to 1 in the infarct-related artery, were randomized to 2.5 mg/kg intravenous CsA (207 patients) or control (203 patients) before percutaneous coronary intervention.

The researcher found that 52.0 percent of CsA patients and 49.0 percent of controls had ST-segment resolution ≥70 percent (P = 0.55). On day four, the median high-sensitivity cardiac troponin T (hs-cTnT) was 2,160 and 2,063 ng/L in the CsA and control group, respectively (P = 0.85). There was no between-group difference in left ventricular (LV) ejection fraction on day four and at six months. The site of infarct did not affect CsA efficacy. No acute allergic reactions were seen, or nonsignificant excesses of six-month mortality (5.7 versus 3.2 percent; P = 0.17) or cardiogenic shock (2.4 versus 1.5 percent; P = 0.33).

"In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction) trial, a single intravenous CsA bolus just before primary percutaneous coronary intervention had no effect on ST-segment resolution or hs-cTnT, and did not improve clinical outcomes or LV remodeling up to six months," the authors write.

One author disclosed financial ties to the pharmaceutical and medical device industries. The CYCLE trial was partially funded by Novartis Italy. Reagents for measuring hs-cTnT were provided by Roche Diagnostics.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Actigraphy May Overestimate Sleep in ICU Setting

Actigraphy May Overestimate Sleep in ICU Setting

Wide ranges of sleep quality and quantity with use of actigraphy among critically ill patients in ICU

Mortality for Unintentional Drug Poisonings Up Since 1979

Mortality for Unintentional Drug Poisonings Up Since 1979

Trajectory of overall mortality rate smooth; no exponential trajectories in rates for individual drugs

Most Breast Cancer Diagnoses Given Over the Phone

Most Breast Cancer Diagnoses Given Over the Phone

This represents a reversal, with in-person diagnoses more common before 2006

is free, fast, and customized just for you!




Already a member?

Sign In Now »